+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Renal Cell Carcinoma Drug"

Advanced Renal Cell Carcinoma - Pipeline Insight, 2024 - Product Thumbnail Image

Advanced Renal Cell Carcinoma - Pipeline Insight, 2024

  • Drug Pipelines
  • February 2024
  • 80 Pages
  • Global
From
From
From
From
Renal cell carcinoma - Epidemiology Forecast to 2032 - Product Thumbnail Image

Renal cell carcinoma - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
From
From
Renal Cell Carcinoma - Pipeline Insight, 2021 - Product Thumbnail Image

Renal Cell Carcinoma - Pipeline Insight, 2021

  • Clinical Trials
  • March 2021
  • 120 Pages
  • Global
From
From
Renal Cell Cancer Pricing, Reimbursement, and Access - Product Thumbnail Image

Renal Cell Cancer Pricing, Reimbursement, and Access

  • Report
  • August 2018
  • 91 Pages
  • Global
From
From
From
From
From
Renal Cell Carcinoma: Epidemiology Forecast to 2028 - Product Thumbnail Image

Renal Cell Carcinoma: Epidemiology Forecast to 2028

  • Report
  • February 2020
  • 46 Pages
  • Global
From
Loading Indicator

Renal Cell Carcinoma (RCC) is a type of cancer that affects the kidneys. It is the most common type of kidney cancer in adults, and is typically treated with drugs that target the cancer cells. These drugs are part of the larger market of drugs used to treat liver and kidney disorders. RCC drugs are typically used in combination with other treatments, such as surgery, radiation, and immunotherapy. They are designed to target the cancer cells and stop them from growing and spreading. Common drugs used to treat RCC include tyrosine kinase inhibitors, mTOR inhibitors, and VEGF inhibitors. The RCC drug market is highly competitive, with many companies developing and marketing drugs to treat the disease. Some of the major players in the market include Pfizer, Novartis, Merck, Bristol-Myers Squibb, and AstraZeneca. Show Less Read more